All In Biotech

Drug Trial Radar · NCT00885404

Chloride High Level Of Resuscitation Infusion Chloride High Level Of Resuscitation Infusion Delivered Evaluation

A Prospective, Before and After Study of the Impact of Lower Chloride Intravenous Fluid Management on Patients' Acid-base Status, Renal Profile,Length of Stay and Mortality.

Last checked: Nov 19, 2026Latest source record: Feb 25, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

7,000

Planned (sponsor's estimate)

Start

Feb 2009

Primary completion

Aug 2009

Study completion Aug 2010

Sponsor

Lead sponsor
Austin HealthGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether intravenous fluid management using lower chloride solutions (Hartmann's solutions and Plasmalyte®) will result in better outcome when compared to management using high chloride solutions (0.9% saline and Gelofusine®).

Conditions

  • Shock
  • Critical Illness

Interventions

  • Lower chloride fluids (Hartmann's solution and Plasmalyte®)Drug

    Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean base excess during hospital stayTime frame: Six month control period (before) and 6 month intervention period (after)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Austin Health

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.